Drug Dev
Akari COO on progress of lead rare disease drug
Clive Richardson, chief operation officer of Akari Therapeutics, speaks to Scrip during the recent BIO-Europe partnering meeting in Berlin about the company's pipeline of potential therapies for orphan inflammatory diseases. Richardson outlines the development timeline for Akari's lead product candidate Coversin, which is most advanced in development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease.